Aktis Oncology (AKTS) vs Latigo Biotherapeutics (LTGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aktis Oncology is the larger company by market cap ($986.7 million vs $980.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | LTGO |
|---|---|---|
| Share price | $17.74 | $14.79 |
| Market cap | $986.69M | $980.57M |
| 1-day change | -1.44% | -4.70% |
| EPS (TTM) | $-1.70 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $25.93 |
| 52-week low | $14.72 | $14.60 |
| Distance from 52-week high | -48.11% | -42.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +99.49% | +253.28% |
| Average volume | 366.06K | 391.26K |
| Shares outstanding | 53.75M | 66.30M |
| Employees | 79 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Latigo Biotherapeutics
LTGO stock →Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
AKTS vs LTGO FAQ
Which is bigger, Aktis Oncology or Latigo Biotherapeutics?
Aktis Oncology (AKTS) is larger, with a market capitalization of $986.69M compared with $980.57M for Latigo Biotherapeutics (LTGO).
Are Aktis Oncology and Latigo Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.